A Filipino-Chinese investing in companies globally

Post navigation

Celgene: Is It a Buy?

Celgene (NASDAQ:CELG), among other biotech companies, has fallen from its record high. The company has returned negative 15% for the past year, and negative 26% from its high of $134 a share back in July 2015 compared to its Tuesday morning price of $96.89 a share. The iShares NASDAQ Biotechnology Index ETF, on the other hand, has performed worst at negative 32% for the past year. Along with leveraged commodity ETFs, the biotech sector has experienced Mr. Market’s dark side. The Standard & Poor’s 500 returned -2% in the same timeframe.

Thanks Jane. I appreciate that. Patience is a must in investing especially in this environment. I would suggest you join this small group we have in Facebook (if you have FB account) and so you could also freely share your ideas (https://www.facebook.com/groups/SeekingValue/). I hope you do well also in your investments.